GSE171591
Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer [HiChIP-Seq]
This study profiles chromatin accessibility, gene expresison, transcription factor binding, and three-dimensional DNA-DNA contact changes upon rapid SWI/SNF ATPase inactivation in prostate cancer cells. SWI/SNF ATPases activity was disabled using a novel PROTAC degrader compound targeting the SMARCA2, SMARCA4 and PBRM1 subunits of the SWI/SNF remodeling complex. Overall design: Distinct prostate cancer cells were treated in vitro with the SMARCA2/4 degrader (AU-15330, abbreviated as AU) for indicated durations (ranging from 4 to 24h) and dosages (ranging from 0.1 - 1uM), and processed for multi-omic characterization.